VVN001 / VivaVision - LARVOL DELTA

VVN001-CCS-301: Study of 5% VVN001 Ophthalmic Solution in Dry Eye Disease (clinicaltrials.gov) - P3 | N=700 | Recruiting | Sponsor: VivaVision Biotech, Inc | Not yet recruiting ➔ Recruiting

Enrollment open • Dry Eye Disease • Ophthalmology

Study of 5% VVN001 Ophthalmic Solution in Dry Eye Disease (clinicaltrials.gov) - P3 | N=700 | Not yet recruiting | Sponsor: VivaVision Biotech, Inc

New P3 trial • Dry Eye Disease • Ophthalmology

Study of VVN001 Ophthalmic Solution in Dry Eye Disease (clinicaltrials.gov) - P2 | N=169 | Completed | Sponsor: VivaVision Biotech, Inc | Phase classification: P2a ➔ P2

Phase classification • Dry Eye Disease • Ophthalmology

A phase 2a, double-masked, randomized, vehicle-controlled trial of VVN001 in subjects with dry eye disease. (PubMed, Ocul Surf) - "There were no major safety issues of note. Appropriately powered studies will be required with a priori selection of the efficacy endpoints to evaluate VVN001's therapeutic potential."

Journal • P2a data • Dry Eye Disease • Infectious Disease • Nephrology • Ophthalmology • Pain

PO103 - A Phase 2a, Double-Masked, Randomized, Vehicle-Controlled Trial of VVN001 in Subjects With DED (AAO 2022) - "Clinically and/or statistically significant dose-related improvement relative to vehicle were seen in corneal staining, Schirmer's Test and SANDE. Adverse event rates were low (≤ 14% mostly ocular) and no greater in active groups than in the vehicle group.ConclusionVVN-001 Ophthalmic solution may be a novel therapeutic for the treatment of dry eye disease."

Clinical • P2a data • Dry Eye Disease • Ophthalmology

Study of VVN001 Ophthalmic Solution in Dry Eye Disease (clinicaltrials.gov) - P2a | N=169 | Completed | Sponsor: VivaVision Biotech, Inc | Active, not recruiting ➔ Completed

Trial completion • Dry Eye Disease • Ophthalmology

Study of VVN001 Ophthalmic Solution in Dry Eye Disease (clinicaltrials.gov) - P2a; N=169; Active, not recruiting; Sponsor: VivaVision Biotech, Inc; Recruiting ➔ Active, not recruiting

Clinical • Enrollment closed • Dry Eye Disease • Ophthalmology

Study of VVN001 Ophthalmic Solution in Dry Eye Disease (clinicaltrials.gov) - P2a; N=165; Recruiting; Sponsor: VivaVision Biotech, Inc; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open • Dry Eye Disease • Ocular Infections • Ophthalmology

The Protective Effects of VVN001 on LPS-Induced Inflammatory Responses in Human RPE Cells and in a Mouse Model of EIU. (PubMed, Inflammation) - "VVN001 alleviated the inflammatory response induced by LPS both in vitro and in vivo. The effect of anti-inflammation is associated with inhibiting the overproduction of ICAM-1 and blocking the activation of NLRP3 inflammasome and the NF-κB signaling pathway."

Journal • Complement-mediated Rare Disorders • Immunology • Inflammation • Ocular Inflammation • Ophthalmology • Uveitis • CXCL8 • ICAM1 • IL18 • IL6

Study of VVN001 Ophthalmic Solution in Dry Eye Disease (clinicaltrials.gov) - P2a; N=165; Not yet recruiting; Sponsor: VivaVision Biotech, Inc

Clinical • New P2a trial • Dry Eye Disease • Ocular Infections • Ophthalmology